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Table 1. Post-AHSCT Patient Toxicities
Patients with
ONJ (N510)
Control Group
(N540) p-value
Febrile days
Mean (Std dev) 2.20 (3.12) 3.30 (3.83) 0.524
Range 0-9 0-15
Lenght of hospital stay in days
Mean (Std dev) 18.20 (7.76) 18.58 (8.44) 0.541
Range 13-38 11-59
Days to ANC engraftment
Mean (Std dev) 10.30 (0.95) 10.58 (1.13) 0.482
Range 9-12 9-15
Days to platelet engraftment
Mean (Std dev) 12.20 (1.62) 12.48 (2.91) 0.776
Range 10-15 10-24
Nausea/Vomiting
Grade 0 (%) 1 (10) 2 (5) 0.753
Grade 1 (%) 3 (30) 21 (52.5)
Grade 2 (%) 6 (60) 15 (37.5)
Grade 3 (%) 0 (0) 2 (5)
Mucositis
Grade 0 (%) 4 (40) 13 (35.5) 0.889
Grade 1 (%) 2 (20) 12 (30)
Grade 2 (%) 3 (30) 11 (27.5)
Grade 3 (%) 1 (10) 4 (10)
Diarrhea
Grade 0 (%) 0 (0) 4 (10) 0.261
Grade 1 (%) 1 (10) 9 (22.5)
Grade 2 (%) 4 (40) 11 (27.5)
Grade 3 (%) 5 (50) 15 (37.5)
Poster Session I S275allogeneicHCT’s. ADV infection was documented in 19 (25%). The
initial site of infection wasGI in 18 andGU in 1. Initial findings were
stool pcr or culture of stool or GI biopsy simultaneous with viremia
in 1. Plasma pcr’s were performed in 11 cases and viremia was found
0-11 days after GI detection in 10. This delay may reflect the way
monitoring was performed rather than any characteristic of ADV in-
fection. All patients except 2 received treatment with CDV 1mg/kg
3x per week. There were 4 cases in 34 patients receiving grafts
from family donors (12%). The incidence in patients receiving
HCT from unrelated donors was 3 fold greater 15/42 (36%). In
both groups 3/4 of ADV infections were preceded by clinically signif-
icant GVHD (3 of 4 sibling HCT and 11 of 15 unrelated HCT).
Since GVHD occurs more commonly after unrelated HCT we
looked at incidence of ADV infection using GVHD and transplant
type as risk factors. 22 of 42 (52%) recipients of unrelated HCT de-
veloped GVHD and 11 ADV infections (50%) occurred in these pa-
tients. Among recipients of relatedHCT 11 of 34 developedGVHD
and 3 of these ADV infection (27%) compared to1 of 23 (4%) devel-
oping ADV without prior GVHD. Most cases developing ADV in-
fection after GVHD had a typical time course, occurring 30-80
days after HCT and 1-8 weeks of steroid therapy. In contrast, 5 cases
occurring without GVHD occurred in patients with congenital im-
mune deficiency or after 2cd and 3rdHCT’s for relapse. Survival was
80% (4 of 5) in patients with ADV infection occurring before or in
absence of GVHD (median 2yr). For patients with GVHD and
ADV infection treatment success was 3 of 11 for unrelated HCT
and 3 of 4 for related HCT. Most deaths were due to combination
of toxicity and GVHD usually after control of ADV infection with
C. ADV infection after HCT correlates closely with GVHD and
unrelated donor graft. Treatment success depends both treatment
of associated GVHD and organ toxicity as it does supression of
ADV.Grade 4 (%) 0 (0) 1 (2.5)
Bacteremia
Yes (%) 3 (30) 12 (30) 1.000
Mean (Std dev) were examined by Student T-test. Frequency (%) were
examined by Mantel-Haenszel Chi-Square.334
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Background: The incidence of bisphosphonate-induced osteonec-
rosis of the jaw (BONJ) in patients with multiple myeloma (MM)
is estimated to be between 5-15%. It is unknown if BONJ canworsen
mucositis or impair its healing. Another concern is that necrotic
bone can harbor bacteria or other microorganisms that can cause
bacteremia and infection during prolonged periods ofmyelosuppres-
sion resulting in more severe toxicity after autologous stem cell
transplantation (AHSCT). The purpose of this study was to deter-
mine if transplant-associated toxicities in patients with BONJ was
different from patients without BONJ.
Patients andMethods:Using a retrospective case-control study de-
sign, 10 MM patients that met diagnostic criteria for BONJ prior to
AHSCT at our institution, between June 2005 and June 2010, were
matched to 40 MM patients without BONJ from our program’s da-
tabase. Patients were matched based on age, stage, gender, ethnicity,
performance status and conditioning regimen prior to AHSCT.
Pre-transplant factors analyzed included: smoking, type of bi-
sphosphonate received and number of infusions, dental extractions
1-year pretransplantation and total edentia. Posttransplant toxicities
analyzed included: mucositis, nausea/vomiting, diarrhea, bacter-
emia, febrile days, engraftment, and length of hospital stay.
Results: The incidence and severity of all toxicities analyzed were
similar in both groups including mucositis, bacteremia and febrile
days (see table). Engraftment and hospital stay were also similar.
Of interest, patients with history of smoking were associated with
a higher risk of BONJ (OR, 4.5; 95% CI, 1.05-19.25, p 5 0.043).
Despite the fact that patients who underwent dental extractions
within one year of AHSCT did not experience a higher risk of
BONJ, total edentia was associated with a significant increase of
BONJ risk (OR, 8.5; 95% CI, 1.83-9.42, p 5 0.006). Type of bi-
sphosphonate and number of infusions received did not increase
the risk of BONJ in our study.Conclusions: Oral and systemic posttransplant complications of
patients with BONJ were similar to patients without BONJ in this
case-control study. The outcome of this study suggests that AHSCT
can be performed safely in patients with BONJ. In our analysis,
patients who smoked and edentulous patients were at higher risk
of developing BONJ.335
EMPRIRICAL ANTIFUNGAL THERAPY OF PERSISTENT NEUTROPENIC FE-
VER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION WITH CASPOFUNGIN OR LIPOSOMAL AMPHOTERICIN B
Sanz, J., Pellicer, D., Montesinos, P., Martinez, D., Salavert, M.,
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Caspofungin and liposomal amphotericin B (L-ampho B) have
shown similar efficacy for the treatment of persistent febrile neutro-
penia (PFN). Although patients undergoing allogeneic stem cell
transplantation (allo-SCT) are at high risk of life-threatening inva-
sive fungal infections (IFI), specific data on the best choice of anti-
fungal agent in this setting are scarce.
The aim of the present study was to analyse the efficacy of caspo-
fungin and L-ampho B used as empirical treatment of PFN in two
consecutive historical cohorts of patients undergoing allo-SCT at
a single institution. Efficacy was evaluated using a five-part compos-
ite end point.
From 2000 to 2009, we analyzed 134 consecutive patients under-
going allo-SCT who received empirical antifungal therapy for the
treatment of PFN: a first cohort of 61 patients treated with L-ampho
B (2000-2004) vs a second cohort of 73 patients treated with caspo-
fungin (2005-2009). Most baseline characteristics were comparable
between both groups. However, patients in the caspofungin group
received more unrelated donor cord blood transplants (63% vs
41%, p 5 0.011).
